10578 studies found for:    NCI
Show Display Options
RSS Create an RSS feed from your search for:
NCI
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer
Conditions: Recurrent Breast Carcinoma;   Stage IV Breast Cancer
Interventions: Biological: Bevacizumab;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis
2 Terminated Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Oligodendroglioma;   Adult Brain Stem Glioma;   Adult Central Nervous System Germ Cell Tumor;   Adult Choroid Plexus Tumor;   Adult Craniopharyngioma;   Adult Diffuse Astrocytoma;   Adult Ependymoblastoma;   Adult Ependymoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Grade I Meningioma;   Adult Grade II Meningioma;   Adult Grade III Meningioma;   Adult Medulloblastoma;   Adult Meningeal Hemangiopericytoma;   Adult Mixed Glioma;   Adult Myxopapillary Ependymoma;   Adult Oligodendroglioma;   Adult Pilocytic Astrocytoma;   Adult Pineoblastoma;   Adult Pineocytoma;   Adult Subependymoma;   Adult Supratentorial Primitive Neuroectodermal Tumor (PNET);   Meningeal Melanocytoma
Interventions: Drug: EF5;   Procedure: conventional surgery;   Procedure: positron emission tomography;   Radiation: fluorine F 18 EF5;   Other: pharmacological study
3 Recruiting WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Conditions: Childhood Solid Neoplasm;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Neuroblastoma
Interventions: Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: WEE1 Inhibitor MK-1775
4 Active, not recruiting Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer
Conditions: Adult Solid Neoplasm;   Peritoneal Carcinomatosis;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Drug: Veliparib
5 Completed Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer
Condition: Recurrent Ovarian Epithelial Cancer
Interventions: Biological: ALVAC-hB7.1;   Biological: recombinant interferon gamma;   Other: laboratory biomarker analysis
6 Completed Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia
Condition: Leukemia
Intervention: Biological: monoclonal antibody Mik-beta-1
7 Completed Broxuridine Plus Surgery in Treating Patients With Stage I or Stage II Prostate Cancer
Conditions: Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer
Interventions: Drug: bromodeoxyuridine;   Procedure: conventional surgery;   Other: laboratory biomarker analysis
8 Active, not recruiting Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
Conditions: Recurrent Uterine Sarcoma;   Uterine Carcinosarcoma
Interventions: Drug: ixabepilone;   Other: laboratory biomarker analysis
9 Completed
Has Results
PXD101 in Treating Patients With Acute Myeloid Leukemia
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Recurrent Adult Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: belinostat;   Other: laboratory biomarker analysis
10 Completed Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Diffuse Adenocarcinoma of the Stomach;   Intestinal Adenocarcinoma of the Stomach;   Mixed Adenocarcinoma of the Stomach;   Recurrent Gastric Cancer;   Stage IIIB Gastric Cancer;   Stage IIIC Gastric Cancer;   Stage IV Gastric Cancer
Interventions: Drug: bortezomib;   Drug: irinotecan hydrochloride;   Other: laboratory biomarker analysis
11 Unknown  Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery
Conditions: Liver and Intrahepatic Biliary Tract Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Unresectable Extrahepatic Bile Duct Cancer
Interventions: Drug: selumetinib;   Other: laboratory biomarker analysis
12 Terminated Entinostat and Anastrozole in Treating Postmenopausal Women With Triple-Negative Breast Cancer That Can Be Removed by Surgery
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: entinostat;   Drug: anastrozole;   Other: diagnostic laboratory biomarker analysis;   Procedure: therapeutic conventional surgery
13 Completed Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: alvocidib;   Drug: docetaxel
14 Active, not recruiting
Has Results
A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer
Conditions: Recurrent Prostate Cancer;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer
Interventions: Biological: sargramostim;   Biological: recombinant vaccinia-TRICOM vaccine;   Biological: fowlpox-PSA-TRICOM vaccine;   Drug: bicalutamide;   Drug: goserelin acetate
15 Completed Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.
Conditions: Epithelial Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatous Mesothelioma;   Stage IA Malignant Mesothelioma;   Stage IB Malignant Mesothelioma;   Stage II Malignant Mesothelioma;   Stage III Malignant Mesothelioma;   Stage IV Malignant Mesothelioma
Interventions: Drug: sorafenib tosylate;   Other: laboratory biomarker analysis
16 Completed Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: dexamethasone;   Drug: pamidronate disodium;   Drug: thalidomide;   Drug: zoledronic acid
17 Completed Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer
Condition: Breast Cancer
Interventions: Drug: acolbifene hydrochloride;   Other: questionnaire administration;   Other: laboratory biomarker analysis
18 Completed R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer
Conditions: Extensive Stage Small Cell Lung Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: R-(-)-gossypol acetic acid;   Drug: cisplatin;   Drug: etoposide
19 Completed flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer
Conditions: Stage IV Melanoma;   Stage IV Renal Cell Cancer;   Recurrent Renal Cell Cancer;   Recurrent Melanoma
Interventions: Drug: flt3 ligand;   Drug: gp100 antigen;   Drug: MART-1 antigen;   Drug: Montanide ISA-51;   Drug: tyrosinase peptide
20 Completed
Has Results
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer
Conditions: Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer;   Stage III Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: tanespimycin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years